MX2010011345A - Polipeptidos modificados del factor ix y usos de los mismos. - Google Patents

Polipeptidos modificados del factor ix y usos de los mismos.

Info

Publication number
MX2010011345A
MX2010011345A MX2010011345A MX2010011345A MX2010011345A MX 2010011345 A MX2010011345 A MX 2010011345A MX 2010011345 A MX2010011345 A MX 2010011345A MX 2010011345 A MX2010011345 A MX 2010011345A MX 2010011345 A MX2010011345 A MX 2010011345A
Authority
MX
Mexico
Prior art keywords
polypeptide
fix
amino acid
glycosylation
factor
Prior art date
Application number
MX2010011345A
Other languages
English (en)
Spanish (es)
Inventor
Alan Brooks
John E Murphy
Marian Seto
Xiaoqiao Jiang
Chandra Patel
Uwe Gritzan
Kornelia Kirchner
Ulrich Haupts
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2010011345A publication Critical patent/MX2010011345A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2010011345A 2008-04-16 2009-04-16 Polipeptidos modificados del factor ix y usos de los mismos. MX2010011345A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US4596108P 2008-04-17 2008-04-17
PCT/US2009/040813 WO2009137254A2 (en) 2008-04-16 2009-04-16 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2010011345A true MX2010011345A (es) 2011-02-23

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011345A MX2010011345A (es) 2008-04-16 2009-04-16 Polipeptidos modificados del factor ix y usos de los mismos.

Country Status (17)

Country Link
EP (1) EP2288622A4 (ru)
JP (1) JP2011517951A (ru)
KR (1) KR20110005862A (ru)
CN (1) CN102083856A (ru)
AU (1) AU2009244633A1 (ru)
BR (1) BRPI0910702A2 (ru)
CA (1) CA2721683A1 (ru)
CO (1) CO6311000A2 (ru)
CR (1) CR11737A (ru)
DO (1) DOP2010000311A (ru)
EC (1) ECSP10010551A (ru)
IL (1) IL208718A0 (ru)
MX (1) MX2010011345A (ru)
RU (1) RU2010146387A (ru)
SG (1) SG189790A1 (ru)
SV (1) SV2010003704A (ru)
WO (1) WO2009137254A2 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN104004739A (zh) * 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
DK2337849T3 (en) * 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
KR20230156435A (ko) 2010-07-09 2023-11-14 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI595004B (zh) * 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
JP5967631B2 (ja) * 2012-04-27 2016-08-10 学校法人日本大学 上皮及び内皮損傷の治療剤
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
US20160289633A1 (en) 2013-12-20 2016-10-06 Biogen Ma Inc. Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
SG10201913278PA (en) 2016-02-01 2020-02-27 Bioverativ Therapeutics Inc Optimized factor viii genes
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
AR110871A1 (es) 2017-01-31 2019-05-08 Bioverativ Therapeutics Inc Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
KR20220009389A (ko) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. 엑소좀 및 aav 의 조성물
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4298737A1 (en) 2021-02-24 2024-01-03 BlueHalo LLC System and method for a digitally beamformed phased array feed
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US6531298B2 (en) * 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
CA2457429A1 (en) * 2001-09-04 2003-03-13 Francis J. Carr Modified factor ix
CA2520970A1 (en) * 2003-04-09 2004-10-28 Robert G. Schaub Hemophilia treatment by inhalation of coagulation factors
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP4738346B2 (ja) * 2003-12-03 2011-08-03 ノヴォ ノルディスク アー／エス ＧｌｙｃｏＰＥＧ化された第ＩＸ因子
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
AU2009244633A1 (en) 2009-11-12
RU2010146387A (ru) 2012-05-27
CN102083856A (zh) 2011-06-01
BRPI0910702A2 (pt) 2016-07-05
IL208718A0 (en) 2010-12-30
CR11737A (es) 2011-02-07
EP2288622A2 (en) 2011-03-02
SV2010003704A (es) 2011-02-21
ECSP10010551A (es) 2010-11-30
KR20110005862A (ko) 2011-01-19
SG189790A1 (en) 2013-05-31
CO6311000A2 (es) 2011-08-22
WO2009137254A3 (en) 2010-01-14
WO2009137254A2 (en) 2009-11-12
CA2721683A1 (en) 2009-11-12
DOP2010000311A (es) 2011-02-28
JP2011517951A (ja) 2011-06-23
EP2288622A4 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
MX2010011345A (es) Polipeptidos modificados del factor ix y usos de los mismos.
US20210277378A1 (en) Coagulation factor ix compositions and methods of making and using same
TWI595004B (zh) 經修飾之第九因子多胜肽及其用途
JP2022171790A (ja) 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
EP3581650A2 (en) Factor ix polypeptide mutant, its uses and a method for its production
JP2013500726A (ja) 改変第ｉｘ因子ポリペプチドおよびその使用
US8513386B2 (en) FVIII-independent FIX-mutant proteins for hemophilia a treatment
JP2020505424A (ja) 因子ｉｘ融合タンパク質ならびにその製造および使用方法
US20120178693A1 (en) Cofactors for Thrombin Activation of Factor VII and Uses Thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal